HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect - Caroline S. Foo, Rana Abdelnabi, Suzanne J. F. Kaptein, Xin Zhang, Sebastiaan ter Horst, Raf Mols, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Pieter Leyssen, Kai Dallmeier, Valentijn Vergote, Elisabeth Heylen, Laura Vangeel, Arnab K. Chatterjee - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Antiviral Research, (202), p. 105311, 2022

DOI: 10.1016/j.antiviral.2022.105311

Links

Tools

Export citation

Search in Google Scholar

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Journal article published in 2022 by Caroline S. Foo, Rana Abdelnabi, Suzanne J. F. Kaptein, Xin Zhang, Sebastiaan ter Horst, Raf Mols, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Pieter Leyssen, Kai Dallmeier, Valentijn Vergote, Elisabeth Heylen, Laura Vangeel, Arnab K. Chatterjee and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO